Eli Lilly, European Medicines Agency

EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly
The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it has benefit in treating a sleep disorder without approving it specifically for the disease,
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with regulators saying Friday that use of the drug is already covered in its approval as a weight-loss medicine.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA). The hea
Lilly's Mounjaro does not need separate indication for sleep apnea, EMA panel determines
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly's (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate indication for the treatment of obstructive sleep apnea (OSA).
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Eloralintide?
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...
STAT4d
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...
Fierce Healthcare3d
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
Verywell Health on MSN21h
Zepbound Helps People Shed More Weight Than Wegovy, According to Eli Lilly Trial
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Yahoo News22h
Ripley County Lilly Scholar announced
Dec. 14—The Ripley County Community Foundation has announced the recipient of the 2025 Lilly Endowment Community Scholarship for Ripley County: Roman Hite. Roman is the son of Rod and Amanda Hite ...